SEC Comment Letter for Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Oct 7, 2019
Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: Oct. 7, 2019 · CIK: 0001228627 · Accession: 0000000000-19-014362
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-34079
Letter
October 7, 2019 Douglas J. Swirsky President, Chief Executive Officer and Director REXAHN PHARMACEUTICALS, INC. 15245 Shady Grove Rd Suite 455 Rockville, Maryland 20850 Re:REXAHN PHARMACEUTICALS, INC. Form 10-K for Fiscal Year Ended December 31, 2018 Filed March 7, 2019 File No. 001-34079 Dear Mr. Swirsky: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
October 7, 2019
Douglas J. Swirsky
President, Chief Executive Officer and Director
REXAHN PHARMACEUTICALS, INC.
15245 Shady Grove Rd
Suite 455
Rockville, Maryland 20850
Re:REXAHN PHARMACEUTICALS, INC.
Form 10-K for Fiscal Year Ended December 31, 2018
Filed March 7, 2019
File No. 001-34079
Dear Mr. Swirsky:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences